NCT02479230View on ClinicalTrials.gov

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 17, 2015

Primary Completion Date

October 30, 2019

Study Completion Date

July 1, 2022

Conditions
Breast CancerMetastatic Breast Cancer
Interventions
BIOLOGICAL

tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine

Given ID

DRUG

gemcitabine hydrochloride

Given IV

Trial Locations (2)

15232

University of Pittsburgh, Pittsburgh

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Joseph Baar, MD, PhD

OTHER

NCT02479230 - Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter